Karyopharm Therapeutics Inc. ·
KPTI 8-K 2026-09-18
Karyopharm Therapeutics Inc. (KPTI) 8-K dated 2026-09-18 — accession 0001193125-26-395517.
Karyopharm Therapeutics Inc. (KPTI) is a biotechnology company listed on US.
Karyopharm Therapeutics Inc. filed a 8-K on 2026-09-18. Accession 0001193125-26-395517.
This 8-K covers: Change to holders' rights (Item 3.03), Bylaws or fiscal year change (Item 5.03), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.
Latest reported KPTI revenue for 2025-12-31 was $146.1M. Net income was -$196.0M. Revenue was up 0.6% from 2024-12-31 to 2025-12-31. KPTI currently screens at market cap $205.6M.
Not investment advice. The KPTI SEC hub lists recent forms. The stock page is the research view.